An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.

Publikation

An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.

Wissenschaftlicher Artikel/Review - 10.10.2023

Singeisen Hélène, Renström Frida, Laimer Markus, Lehmann Roger, Bilz Stefan, Brändle Michael

Zitation

Singeisen H, Renström F, Laimer M, Lehmann R, Bilz S, Brändle M. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study. Eur J Prev Cardiol 2023; 30:1473-1481.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur J Prev Cardiol 2023; 30

Veröffentlichungsdatum

10.10.2023

eISSN (Online)

2047-4881

Seiten

1473-1481

Kurzbeschreibung/Zielsetzung

In 2019, the European Society of Cardiology/European Atherosclerosis Society updated the 2016 guidelines for the management of dyslipidaemias recommending more stringent low-density lipoprotein cholesterol (LDL-C) targets in diabetes mellitus type 2 (DM2). Based on a real-world patient population, this study aimed to determine the feasibility and cost of attaining guideline-recommended LDL-C targets, and assess cardiovascular benefit.